Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (271-280 of 384) with videos related to

Pageof 39
Sort By:
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Scientific Reports|March 15, 2026
CCR7 immune cell receptor expression in inflammatory breast cancerJennifer H Chen, Wintana Balema, Savitri Krishnamurthy, et al.
Blood Advances|May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Blood Advances|July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Blood|May 17, 2003
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyClaudia D Baldus, Stephan M Tanner, Amy S Ruppert, et al.
Journal of Geriatric Oncology|November 1, 2019
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Pageof 39

Showing results (271-280 of 384) with videos related to

Sort By:
Pageof 39
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Scientific Reports|March 15, 2026
CCR7 immune cell receptor expression in inflammatory breast cancerJennifer H Chen, Wintana Balema, Savitri Krishnamurthy, et al.
Blood Advances|May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Blood Advances|July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Blood|May 17, 2003
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyClaudia D Baldus, Stephan M Tanner, Amy S Ruppert, et al.
Journal of Geriatric Oncology|November 1, 2019
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Pageof 39